Abstract: A solid oral pharmaceutical composition is disclosed, which comprises: a first active ingredient, which is pitavastatin or a pharmaceutically acceptable salt thereof; a second active ingredient, which is ezetimibe or a pharmaceutically acceptable salt thereof; and at least one excipient, including a diluent, a stabilizing agent, a disintegrant, a binding agent, a sweetener, a lubricant, a glidant, a flavor, a coloring agent or a combination thereof.
Type:
Grant
Filed:
August 5, 2021
Date of Patent:
December 5, 2023
Assignee:
ORIENT PHARMA CO., LTD.
Inventors:
Chien-Yu Chen, David Wong, Mongkol Sriwongjanya
Abstract: The present invention provides multi-layer capsules and manufacture methods thereof Different materials are added in sequence into a capsule to form a multi-layer capsule without diffusion and/or interaction between layers.
Abstract: An alpha2 adrenoreceptor agonist eg. clonidine, brimonidine, monoxidine, lofexidine is useful for the treatment of siaiorrhoea, administered by the paraungual, sublingual or buccal route. The patient to be treated is also given an anti-muscarinic agent eg. oxybutynin, glycopyrrolate, ipratropium.
Abstract: Disclosed is a pharmaceutical composition comprising pitavastatin, or its salt or ester and MgO, of which the aqueous solution or dispersion has pH of from 10 to 10.8. The composition has good time-dependent stability and has no change in its outward appearance even after having been stored long.
Type:
Application
Filed:
April 17, 2013
Publication date:
November 21, 2013
Applicant:
ORIENT PHARMA CO., LTD.
Inventors:
Yu-Chien Hsiao, Chi-Tai Chang, Che-Chin Lin
Abstract: An alpha2 adrenoreceptor agonist eg. clonidine, brimonidine, monoxidine, lofexidine is useful for the treatment of sialorrhoea, administered by the paraungual, sublingual or buccal route. The patient to be treated is also given an anti-muscarinic agent eg. oxybutynin, glycopyrrolate, ipratropium.
Abstract: An alpha2 adrenoreceptor agonist eg. clonidine, brimonidine, monoxidine, lofexidine is useful for the treatment of siaiorrhoea, administered by the paraungual, sublingual or buccal route. The patient to be treated is also given an anti-muscarinic agent eg. oxybutynin, glycopyrrolate, ipratropium.
Abstract: The present invention is directed to compositions and methods for the transdermal delivery of a pharmaceutically active compound. In some embodiments, the addition of inert pharmaceutical ingredients in place of a portion of adhesive in a transdermal patch formulation increases the rate of skin permeation of a pharmaceutical compound.
Abstract: The present invention is directed to compositions for the sustained delivery of an antibiotic, for example vancomycin, to achieve desirable release profiles. This application is also directed to methods of using the compositions and processes for manufacturing the compositions.